Across its top 20 institutional holders, PMCB's holder base skews toward low-concentration, high-turnover investors on average (avg. concentration score 13/100, avg. turnover score 54/100).

Quarterly Activity

Recent Activity

+$580.3K

Total Buy Value

$313.0K

Total Sell Value

New buy7

Trim7

Add6

Sold out5

Net Buyers

Net Sellers

Smart Money Convergence

PMCB does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/PMCB

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

71715X203

FAQ

Who are the top institutional investors holding PHARMACYTE BIOTECH INC (PMCB)?

Major stakeholders currently include Citadel Advisors LLC ($345.8K), Geode Capital Management, LLC ($130.2K), Renaissance Technologies LLC ($37.6K). Based on the latest 13F filings, there are a total of 31 tracked investment funds and institutions maintaining positions in PMCB.

What is the overall institutional sentiment toward PMCB recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $29.9K, driven by 13 managers accumulating shares while 12 reduced their exposure.

Which institutions have been selling or reducing their PMCB positions?

In the latest period, 7 funds trimmed their holdings, and 5 managers completely exited their positions. The aggregate reported sell value was $313.0K.

Are there any notable investors adding PMCB to their portfolios?

Yes, buying activity remains notable. 7 institutions opened new positions in {ticker}, and 6 existing holders added to their shares. The total reported buy value for the quarter amounted to $580.3K.